[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611564":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":24,"locations":30,"responsibleParty":53,"collaborators":24,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":24,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":24,"studyType":70,"phases":71,"briefSummary":74,"conditions":75,"keywords":24,"overallStatus":33,"whyStopped":24,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","ACTIVE_COMPARATOR","25 patients received the standard conventional therapy in addition to placebo for 3 months.",[13],"Other: Standard Therapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Erdosteine group","25 patients were given the standard conventional therapy plus erdostiene 300 mg two times daily.",[13,18],"Drug: Erdosteine",[20,25],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"Standard Therapy","• The standard conventional therapy in both groups included regular exercise in the form of any physical activity as walking, cycling, etc. for 30-45 minutes minimum 5 days per week in addition to calorie restriction in overweight and obese patients (1200-1500 and 1000-1200 kcal\u002Fday for men and women, respectively).",[9,15],null,{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":24},"DRUG","Erdosteine","Erdosteine is an oral mucoactive agent with antioxidant and anti-inflammatory properties that also reduces bacterial adhesiveness and enhances the effects of antibiotic therapy, all of these properties may be useful for the prevention and treatment of COPD exacerbations",[15],[31],{"facility":32,"status":33,"city":34,"state":24,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Tanta Unuversity","RECRUITING","Tanta","31527","Egypt","EG",{"type":39,"coordinates":40},"Point",[41,42],31.00192,30.78847,{"lat":42,"lon":41},[45,50],{"name":46,"role":47,"phone":48,"phoneExt":24,"email":49},"Mostafa M I Bahaa, PhD","CONTACT","0201025538337","mbahaa@horus.edu.eg",{"name":51,"role":52,"phone":24,"phoneExt":24,"email":24},"Mostafa M Bahaa, PhD","SUB_INVESTIGATOR",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Mostafa Bahaa","Lecturer","100611564","phase-1-erdosteine-in-the-treatment-of-nonalcoholic-fatty-liver-disease-100611564",false,"NCT07242222","Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease","Evaluating the Safety and Efficacy of Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients","Inclusion Criteria:\n\nEither male or female adult patients (\\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography (US).\n\nExclusion Criteria:\n\nPregnant and\u002For lactating women, excessive alcohol use (defined as an average alcohol intake \\> 30 g per day in men and \\> 20 g per day in women).\n\nOther etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, and autoimmune hepatitis.\n\nPatients suffering from chronic kidney disease, hyper\u002Fhypoparathyroidism. Hypersensitivity to erdostiene.","ALL","18 Years","60 Years",{"count":68,"type":69},50,"ESTIMATED","INTERVENTIONAL",[72,73],"PHASE1","PHASE2","Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries (1). NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity). According to the Clinical Practice Guidelines of the European Association for the Study of the Liver, the diagnosis of NAFLD requires the exclusion of daily alcohol consumption \\>30 g for men and \\>20 g for women",[76],"Fatty Liver","2025-12-03",{"date":79,"type":80},"2025-12-10","ACTUAL",{"date":82,"type":80},"2025-11-20",{"date":84,"type":69},"2026-11-20",{"name":5,"class":6},1]